Clarivate PLC (CLVT): Price and Financial Metrics
CLVT Price/Volume Stats
| Current price | $7.17 | 52-week high | $10.03 |
| Prev. close | $7.14 | 52-week low | $6.07 |
| Day low | $7.09 | Volume | 314,649 |
| Day high | $7.18 | Avg. volume | 4,058,841 |
| 50-day MA | $7.53 | Dividend yield | N/A |
| 200-day MA | $7.80 | Market Cap | 4.79B |
CLVT Stock Price Chart Interactive Chart >
Clarivate PLC (CLVT) Company Bio
Clarivate Plc engages in the provision of trusted insights and analytics to accelerate the pace of innovation. It operates through the Science and Intellectual Property segments. The Science segment comprises the academic and life science product lines. The Intellectual Property segment includes patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London.
Latest CLVT News From Around the Web
Below are the latest news stories about CLARIVATE PLC that investors may wish to consider to help them evaluate CLVT as an investment opportunity.
Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment ParadigmClarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series, Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the |
Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug DevelopmentClarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence by Clarivate. The integrated workflow provides customers with a diverse array of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more. |
Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 ListClarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today revealed its 2023 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. |
Clarivate to Present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today that Jonathan Gear, Chief Executive Officer, will present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on Tuesday, November 14, 2023 at 1:20 pm Eastern Time. |
Clarivate Reports Third Quarter 2023 ResultsClarivate Plc - (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today reported results for the third quarter. |
CLVT Price Returns
| 1-mo | -0.55% |
| 3-mo | -18.80% |
| 6-mo | 12.74% |
| 1-year | -17.40% |
| 3-year | -72.39% |
| 5-year | N/A |
| YTD | -22.57% |
| 2023 | 11.03% |
| 2022 | -64.54% |
| 2021 | -20.83% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...